We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
ISTURISA (Recordati Rare Diseases Australia Pty Ltd)
Product name
ISTURISA
Date registered
Evaluation commenced
Decision date
Approval time
122 (255 working days)
Active ingredients
osilodrostat phosphate
Registration type
NCE/NBE
Indication
ISTURISA (film-coated tablet) is indicated for the treatment of endogenous Cushing's syndrome in adults.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.